Table 2.
In vivo anti-glioma efficacy of different PTX formulations on intracranial U87MG glioma mice model (n = 9).
| Groups | Dose (mg/kg) | MSTa (days) | Median (days) | Compare with salineb | Compare with Taxolb | Compare with PEG-PSNPsb |
|---|---|---|---|---|---|---|
| Saline | ― | 17.4 ± 0.9 | 18 | ― | ― | ― |
| Taxol | 10 | 20.3 ± 1.0 | 20 | * | ― | ― |
| PEG-PSNPs | 10 | 27.6 ± 1.4 | 27 | *** | *** | ― |
| PEG-PSNPs +borneol | 10 | 32.7 ± 1.9 | 32 | *** | *** | * |
| CGKRK-PSNPs | 10 | 35.4 ± 2.2 | 33 | *** | *** | ** |
| CGKRK-PSNPs +borneol | 10 | 38.9 ± 2.3 | 39 | *** | *** | *** |
a
MST, mean survival time.
b
*P < 0.05, **P < 0.01, ***P < 0.001 of log-rank analysis.